IL MIELOMA MULTIPLO. RUOLA DEI FATTORI PROGNOSTICI E DELLA STADIAZIONE IN UN PROGRAMMA TERAPEUTICO

Translated title of the contribution: Advances in staging and therapy of multiple myeloma

S. Bolis, E. R. Bregani, F. Rossini, I. Casaroli, E. Lanzi, P. Maffe, L. Baldicchi, L. Borin, S. Mingozzi, P. Tripputi, E. M. Pogliani, G. Corneo

Research output: Contribution to journalArticle

Abstract

Patients affected with multiple myeloma constitute an heterogeneous population with very different clinical patterns, varying from asymptomatic to very compromised patients with severe and uncontrolled disease. Most common clinical and biological staging systems have been in use for many years. Recently new prognostic factors have been identified; among them, serum levels of beta-2 microglobuline, C-reactive protein and interleukine-6 employed with already known parameters have been useful in the new staging system, permitting a more focalized therapy. As today is not yet possible to define the best treatment schedule, as the most common treatments are incapable to eradicate myeloma neoplastic clone even in responsive patients. Nevertheless extensive use of biologic response modifiers in the last years, as alpha interferon, have added new powerful and hopeful therapeutic tools even if the results need to be confirmed in future trials. It's important to remind the primary role of bone marrow transplantation associated with high dose polichemiotherapy even if just a minority of patients is eligible for this therapeutic chance.

Original languageItalian
Pages (from-to)49-55
Number of pages7
JournalRecenti Progressi in Medicina
Volume85
Issue number1
Publication statusPublished - 1994

Fingerprint

Multiple Myeloma
Therapeutics
Bone Marrow Transplantation
Interferon-alpha
C-Reactive Protein
Appointments and Schedules
Clone Cells
Serum
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bolis, S., Bregani, E. R., Rossini, F., Casaroli, I., Lanzi, E., Maffe, P., ... Corneo, G. (1994). IL MIELOMA MULTIPLO. RUOLA DEI FATTORI PROGNOSTICI E DELLA STADIAZIONE IN UN PROGRAMMA TERAPEUTICO. Recenti Progressi in Medicina, 85(1), 49-55.

IL MIELOMA MULTIPLO. RUOLA DEI FATTORI PROGNOSTICI E DELLA STADIAZIONE IN UN PROGRAMMA TERAPEUTICO. / Bolis, S.; Bregani, E. R.; Rossini, F.; Casaroli, I.; Lanzi, E.; Maffe, P.; Baldicchi, L.; Borin, L.; Mingozzi, S.; Tripputi, P.; Pogliani, E. M.; Corneo, G.

In: Recenti Progressi in Medicina, Vol. 85, No. 1, 1994, p. 49-55.

Research output: Contribution to journalArticle

Bolis, S, Bregani, ER, Rossini, F, Casaroli, I, Lanzi, E, Maffe, P, Baldicchi, L, Borin, L, Mingozzi, S, Tripputi, P, Pogliani, EM & Corneo, G 1994, 'IL MIELOMA MULTIPLO. RUOLA DEI FATTORI PROGNOSTICI E DELLA STADIAZIONE IN UN PROGRAMMA TERAPEUTICO', Recenti Progressi in Medicina, vol. 85, no. 1, pp. 49-55.
Bolis, S. ; Bregani, E. R. ; Rossini, F. ; Casaroli, I. ; Lanzi, E. ; Maffe, P. ; Baldicchi, L. ; Borin, L. ; Mingozzi, S. ; Tripputi, P. ; Pogliani, E. M. ; Corneo, G. / IL MIELOMA MULTIPLO. RUOLA DEI FATTORI PROGNOSTICI E DELLA STADIAZIONE IN UN PROGRAMMA TERAPEUTICO. In: Recenti Progressi in Medicina. 1994 ; Vol. 85, No. 1. pp. 49-55.
@article{f4b22ca505f644a498488bbf839d1dde,
title = "IL MIELOMA MULTIPLO. RUOLA DEI FATTORI PROGNOSTICI E DELLA STADIAZIONE IN UN PROGRAMMA TERAPEUTICO",
abstract = "Patients affected with multiple myeloma constitute an heterogeneous population with very different clinical patterns, varying from asymptomatic to very compromised patients with severe and uncontrolled disease. Most common clinical and biological staging systems have been in use for many years. Recently new prognostic factors have been identified; among them, serum levels of beta-2 microglobuline, C-reactive protein and interleukine-6 employed with already known parameters have been useful in the new staging system, permitting a more focalized therapy. As today is not yet possible to define the best treatment schedule, as the most common treatments are incapable to eradicate myeloma neoplastic clone even in responsive patients. Nevertheless extensive use of biologic response modifiers in the last years, as alpha interferon, have added new powerful and hopeful therapeutic tools even if the results need to be confirmed in future trials. It's important to remind the primary role of bone marrow transplantation associated with high dose polichemiotherapy even if just a minority of patients is eligible for this therapeutic chance.",
keywords = "alpha-interferon, beta-2 microglobuline, C-reactive protein, interleukine 6, multiple myeloma",
author = "S. Bolis and Bregani, {E. R.} and F. Rossini and I. Casaroli and E. Lanzi and P. Maffe and L. Baldicchi and L. Borin and S. Mingozzi and P. Tripputi and Pogliani, {E. M.} and G. Corneo",
year = "1994",
language = "Italian",
volume = "85",
pages = "49--55",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "1",

}

TY - JOUR

T1 - IL MIELOMA MULTIPLO. RUOLA DEI FATTORI PROGNOSTICI E DELLA STADIAZIONE IN UN PROGRAMMA TERAPEUTICO

AU - Bolis, S.

AU - Bregani, E. R.

AU - Rossini, F.

AU - Casaroli, I.

AU - Lanzi, E.

AU - Maffe, P.

AU - Baldicchi, L.

AU - Borin, L.

AU - Mingozzi, S.

AU - Tripputi, P.

AU - Pogliani, E. M.

AU - Corneo, G.

PY - 1994

Y1 - 1994

N2 - Patients affected with multiple myeloma constitute an heterogeneous population with very different clinical patterns, varying from asymptomatic to very compromised patients with severe and uncontrolled disease. Most common clinical and biological staging systems have been in use for many years. Recently new prognostic factors have been identified; among them, serum levels of beta-2 microglobuline, C-reactive protein and interleukine-6 employed with already known parameters have been useful in the new staging system, permitting a more focalized therapy. As today is not yet possible to define the best treatment schedule, as the most common treatments are incapable to eradicate myeloma neoplastic clone even in responsive patients. Nevertheless extensive use of biologic response modifiers in the last years, as alpha interferon, have added new powerful and hopeful therapeutic tools even if the results need to be confirmed in future trials. It's important to remind the primary role of bone marrow transplantation associated with high dose polichemiotherapy even if just a minority of patients is eligible for this therapeutic chance.

AB - Patients affected with multiple myeloma constitute an heterogeneous population with very different clinical patterns, varying from asymptomatic to very compromised patients with severe and uncontrolled disease. Most common clinical and biological staging systems have been in use for many years. Recently new prognostic factors have been identified; among them, serum levels of beta-2 microglobuline, C-reactive protein and interleukine-6 employed with already known parameters have been useful in the new staging system, permitting a more focalized therapy. As today is not yet possible to define the best treatment schedule, as the most common treatments are incapable to eradicate myeloma neoplastic clone even in responsive patients. Nevertheless extensive use of biologic response modifiers in the last years, as alpha interferon, have added new powerful and hopeful therapeutic tools even if the results need to be confirmed in future trials. It's important to remind the primary role of bone marrow transplantation associated with high dose polichemiotherapy even if just a minority of patients is eligible for this therapeutic chance.

KW - alpha-interferon

KW - beta-2 microglobuline

KW - C-reactive protein

KW - interleukine 6

KW - multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=0028183188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028183188&partnerID=8YFLogxK

M3 - Articolo

C2 - 8184181

AN - SCOPUS:0028183188

VL - 85

SP - 49

EP - 55

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 1

ER -